目前,包括微管蛋白结合剂紫杉烷类和长春碱类药物在内的许多抗肿瘤药,因缺乏选择性,均会导致各种不良反应。因此,开发更具特异性的新型抗肿瘤药,已成为广大药学研究者的当务之急。Polo样激酶家族成员PLK1是近年来备受人们关注的肿瘤 Currently, many anti-tumor drugs, including tubulin binding agents taxanes and vinca alkaloids, can cause various adverse reactions due to lack of selectivity. Therefore, the development of more specific new antineoplastic agents, has become the top priority for the majority of pharmaceutical researchers. PLK1, a member of the Polo-like kinase family, has attracted much attention in recent years